Articles related to VACCINES/IMMUNIZATION

This study from Cleveland Clinic highlights a counterintuitive trend where higher numbers of COVID-19 vaccine doses could lead to increased risk of infection, underscoring the complexity of immune responses and vaccine effectiveness over time.

Recent systematic reviews suggest a subtle increase in NMOSD and MS risks post-COVID-19 vaccination, primarily affecting genetically susceptible individuals.

Recent research indicates a rise in cancer mortality following the third dose of mRNA COVID-19 vaccines, especially in types linked to estrogen sensitivity. This underscores the need for ongoing surveillance and research into the long-term effects of mRNA vaccines on cancer progression.

“In light of recent findings, it is crucial to evaluate the implications of modified mRNA in therapeutic uses, particularly its role in immune response and potential cancer progression.”

With a significant rise in meningococcal disease cases in 2023 and continuing into 2024, physicians must be alert for non-traditional symptoms such as septic arthritis and bacteremia to ensure timely and effective patient management.

In a recent phase 2–3 trial, nirmatrelvir–ritonavir did not significantly shorten the time to COVID-19 symptom resolution compared to placebo, yet it demonstrated a trend towards reduced hospitalization and death rates, emphasizing the importance of tailored treatment strategies.